Further Upside For Keeps Biopharma Inc. (KOSDAQ:256940) Shares Could Introduce Price Risks After 33% Bounce

Keeps Biopharma Inc. (KOSDAQ:256940) shares have continued their recent momentum with a 33% gain in the last month alone. The last month tops off a massive increase of 103% in the last year.

Although its price has surged higher, you could still be forgiven for feeling indifferent about Keeps Biopharma's P/S ratio of 1.7x, since the median price-to-sales (or "P/S") ratio for the Semiconductor industry in Korea is also close to 1.2x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.

We've discovered 4 warning signs about Keeps Biopharma. View them for free.

See our latest analysis for Keeps Biopharma

What Does Keeps Biopharma's Recent Performance Look Like?

Keeps Biopharma could be doing better as it's been growing revenue less than most other companies lately. Perhaps the market is expecting future revenue performance to lift, which has kept the P/S from declining. However, if this isn't the case, investors might get caught out paying too much for the stock.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Keeps Biopharma.

Is There Some Revenue Growth Forecasted For Keeps Biopharma?

Keeps Biopharma's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.

If we review the last year of revenue growth, the company posted a terrific increase of 38%. This great performance means it was also able to deliver immense revenue growth over the last three years. Accordingly, shareholders would have been over the moon with those medium-term rates of revenue growth.

Looking ahead now, revenue is anticipated to climb by 79% during the coming year according to the only analyst following the company. With the industry only predicted to deliver 31%, the company is positioned for a stronger revenue result.

With this information, we find it interesting that Keeps Biopharma is trading at a fairly similar P/S compared to the industry. It may be that most investors aren't convinced the company can achieve future growth expectations.

The Key Takeaway

Keeps Biopharma's stock has a lot of momentum behind it lately, which has brought its P/S level with the rest of the industry. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

Despite enticing revenue growth figures that outpace the industry, Keeps Biopharma's P/S isn't quite what we'd expect. When we see a strong revenue outlook, with growth outpacing the industry, we can only assume potential uncertainty around these figures are what might be placing slight pressure on the P/S ratio. However, if you agree with the analysts' forecasts, you may be able to pick up the stock at an attractive price.

Before you take the next step, you should know about the 4 warning signs for Keeps Biopharma (1 is potentially serious!) that we have uncovered.

If these risks are making you reconsider your opinion on Keeps Biopharma, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.